Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Scrip and IQVia explore how Brexit will impact clinical trials, product launches and funding in the UK.
With the UK deadline to leave the European Union just over 12 months away, UK companies will see access to European Investment Fund-backed venture capital restricted. Quality companies, however, should not be fearful.
Latest From Brexit
Ipsen's David Meek tells Scrip a Hard Brexit looks likely and that he's preparing the French pharma for that scenario.
BIO Notebook Day 4: Gottlieb Seeks Early Engagement On Gene Therapy; Ireland’s Brexit Opportunities; AMAG’s Bremelanotide Strategy; Alzheimer’s ‘Learnings’
US FDA to head off cell/gene therapy manufacturing issues with pre-IND meetings; Republic of Ireland will “chase any opportunities” for business partners stemming from Brexit, even while hoping UK reconsiders EU departure; AMAG won’t follow the flibanserin PR approach with newly submitted female sexual dysfunction drug bremelanotide; United Neuroscience CMO Ajay Verma says Alzheimer’s trial setbacks are “learnings,” with progress toward novel therapies moving faster than it has for cancer and HIV.
The pharmaceutical sector has given its backing to a report from MPs which warns that a no-deal Brexit will have a hugely damaging effect on the industry in the country, turning it into "a second-tier state for new and innovative medicines."
As we enter a new year, Scrip reviews some of the biggest overall themes which attracted our readers over the last 12 months.
From ongoing progress in IO to revolutions in AI, and from pricing headaches to new therapies for migraine: Scrip has gleaned from experts and industry executives their expectations and predictions for 2018's hot topics. Here is our digest.
MSD's R&D head Roger Perlmutter and Sir John Bell tell Scrip the UK government needs to offer better manufacturing incentives to the life science sector and also encourage more efficient drug innovation there.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.